This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Inflectra® (infliximab) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

NOR-SWITCH efficacy

NOR-SWITCH was a randomised, double-blind, non-inferiority parallel-group study that compared the effect of switching from Remicade® to Inflectra/CT-P13* (infliximab) in 481 patients across all indications.§1

Primary endpoints: Disease worsening across all indications at Week 52.

Non inferiority in disease worsening1

Disease worsening at Week 52#1

Per-protocol set population.
​​​​​​​Created from Jørgensen KK, et al. 2017.

Stable patients switching to CT-P13* experienced a similar percentage of disease worsening when measured across all indications compared to those remaining on Remicade® therapy.§1

Explore more

Crohn’s disease safety

Learn about the safety profile of Inflectra in patients with Crohn’s disease

Learn more

Optimising treatment with Inflectra

Learn more about TDM and biomarkers

Find out more


†Remicade® is a registered trademark of MSD.
*CT-P13 is marketed under different brand names including Inflectra and REMSIMA®.
§Only single one-way switching from Remicade® to CT-P13* was examined in this study. The NOR-SWITCH trial included only patients on Remicade® and CT-P13*; its findings do not support that any other biosimilars of infliximab can achieve the same result.
‡According to a pre-specified margin of 15%. The study was not powered to show non-inferiority in individual diseases.
#Primary endpoint.
CI=Confidence interval; TNF=Tumour necrosis factor.
References
  1. Jørgensen KK, et al. Lancet 2017. 389:2304–2316.
PP-IFA-GBR-0421. March 2021

Quick Links

  • GONCZI L et al

  • Study 3.4

  • NOR-SWITCH safety

  • NOR-SWITCH efficacy

  • PROSIT-BIO safety

  • PROSIT-BIO efficacy

  • PROSIT-BIO study design

  • Switch studies

  • Paediatric studies

  • Induction & Maintenance

  • Inflammatory bowel disease

Learn about the mechanism of action of Infliximab.

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Find out more

** This is an optional area where footnotes can live.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No